Importantly, ATRX mutations were more common in pituitary carcinomas (28%) than in aggressive but non-metastatic tumors (13%), supporting the hypothesis that ATRX loss contributes to metastatic potential. This evidence concerns the gene ATRX and pituitary adenocarcinoma.